BDA-366
BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1].
Product Specifications
CAS Number
[1909226-00-1]
UNSPSC
12352005
Hazard Statement
H302
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bda-366.html
Purity
98.42
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C(NC[C@H]3CO3)=CC=C2NC[C@H](O)CN(CC)CC)C(C4=CC=CC=C41)=O
Molecular Formula
C24H29N3O4
Molecular Weight
423.50
Precautions
H302
References & Citations
[1]Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27 (6) :852-863.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Phospho-LSP1 (Ser204) Polyclonal Antibody, Biotin Conjugated
